Jim Simons
TXMD icon

Jim Simons’s TherapeuticsMD TXMD Stock Holding History

Jim Simons’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$295K Buy
146,200
+49,700
+52% +$112K ﹤0.01% 2796
2025
Q4 		$157K Buy
96,500
+61,000
+172% +$88.2K ﹤0.01% 2928
2025
Q3 		$38.2K Buy
35,500
+20,600
+138% +$23.1K ﹤0.01% 3374
2025
Q2 		$17.3K Buy
14,900
+1,400
+10% +$1.7K ﹤0.01% 3477
2025
Q1 		$12.5K Buy
13,500
+2,609
+24% +$2.6K ﹤0.01% 3383
2024
Q4 		$9.37K Buy
+10,891
New +$15.3K ﹤0.01% 3520
2024
Q2 		– Sell
-13,700
Closed -$31K – 3969
2024
Q1 		$31K Buy
+13,700
New +$31.7K ﹤0.01% 3550
2022
Q2 		– Sell
-62,952
Closed -$1.2M – 4583
2022
Q1 		$1.2M Buy
62,952
+44,626
+244% +$702K ﹤0.01% 2614
2021
Q4 		$326K Sell
18,326
-11,372
-38% -$341K ﹤0.01% 3302
2021
Q3 		$1.1M Buy
+29,698
New +$1.32M ﹤0.01% 2495
2018
Q2 		– Sell
-3,662
Closed -$892K – 3535
2018
Q1 		$892K Buy
+3,662
New +$1.03M ﹤0.01% 2698
2016
Q1 		– Sell
-10,594
Closed -$5.49M – 3535
2015
Q4 		$5.49M Buy
+10,594
New +$3.91M 0.01% 1408

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jim Simons's TXMD Position: Q1 2026 in Review

Jim Simons increased its TherapeuticsMD (TXMD) stake by 52% in Q1 2026, buying an estimated $112K and bringing the position to 146,200 shares worth $295K. The position accounts for ﹤0.01% of the portfolio, ranked #2796.

Jim Simons first reported a position in TXMD in Q4 2015 and has held it in 12 quarters since. The position peaked at $5.49M in Q4 2015. 49 funds tracked by Wall St. Rank hold TXMD as of Q1 2026.

  • Jim Simons held 146,200 shares of TherapeuticsMD worth $295K as of Q1 2026.
  • Jim Simons bought 49,700 TherapeuticsMD shares in Q1 2026, an estimated $112K.
  • TherapeuticsMD made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2796 holding.
  • Jim Simons first reported a position in TherapeuticsMD in Q4 2015 and has held it in 12 quarters since.
  • Jim Simons's TherapeuticsMD position peaked at $5.49M in Q4 2015.
  • 49 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.